Double Strand and Deliver | GenomeWeb

Double Strand and Deliver

Premium
When Tom Tuschl and colleagues broke the story about RNA interference in mammalian cells, it didn’t take long for researchers to start thinking about the possibility of harnessing this gene silencing technology for human disease. At this point, most in the know agree that the last major hurdle is one of delivery. A bit of chemistry, a bit of biology, and a whole lot of experimentation have resulted in several promising avenues — and even some RNAi-based drug clinical trials.
 

Get the full story with
GenomeWeb Premium

Only $95 for the
first 90 days*

A trial upgrade to GenomeWeb Premium gives you full site access, interest-based email alerts, access to archives, and more. Never miss another important industry story.

Try GenomeWeb Premium now.

Already a GenomeWeb Premium member? Login Now.
Or, See if your institution qualifies for premium access.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Register for Free Content
You can still register for access to our free content.

In Science this week: metagenomic-based technique for determining protein structure, and more.

An academic laments the rise of narcissism in the sciences, the Guardian reports.

Outgoing FDA commissioner Robert Califf writes in an editorial that the agency can help boost innovation.

The Trump transition team has asked NIH Director Francis Collins to remain at his post, though it's unclear for how long that will be.